home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410e.zip
/
M94B0809.TXT
< prev
next >
Wrap
Text File
|
1994-11-11
|
2KB
|
30 lines
Document 0809
DOCN M94B0809
TI Novel mutation (V75T) in human immunodeficiency virus type 1 reverse
transcriptase confers resistance to
2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
DT 9412
AU Lacey SF; Larder BA; Antiviral Therapeutic Research Unit, Wellcome
Research; Laboratories, Beckenham, United Kingdom.
SO Antimicrob Agents Chemother. 1994 Jun;38(6):1428-32. Unique Identifier :
AIDSLINE MED/94379807
AB We have selected a human immunodeficiency virus type 1 (HIV-1) mutant
strain with a moderate (sevenfold) level of resistance to the nucleoside
analog 2',3'-didehydro-2',3'-dideoxythymidine (D4T or stavudine). After
serial passage of the HXB2 strain of HIV-1 in MT4 cells, a novel
mutation involving two nucleotide substitutions in codon 75 of the viral
reverse transcriptase, altering valine to threonine, was seen. When
introduced into a wild-type HIV-1 background by site-directed
mutagenesis, the T-75 mutation conferred cross-resistance to the
dideoxynucleosides dideoxyinosine and dideoxycytosine as well as to
2',3'-didehydro-2',3'-dideoxycytosine.
DE Base Sequence Cells, Cultured Drug Resistance, Microbial Hela Cells
Human HIV-1/*DRUG EFFECTS/ENZYMOLOGY/GENETICS Molecular Sequence Data
*Mutation Reverse Transcriptase/ANTAGONISTS & INHIB/*GENETICS
Stavudine/*PHARMACOLOGY Zalcitabine/ANALOGS & DERIVATIVES/PHARMACOLOGY
Zidovudine/PHARMACOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).